# Vaccination for Recovered Inpatients with COVID-19 (VATICO)

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2021 · $15,147,252

## Abstract

The “SARS-Cov-2 Vaccination Strategies In Previously Hospitalized And Recovered COVID-19 Patients” clinical trial known as “VATICO” is assessing the optimal timing and number of mRNA COVID-19 vaccinations for patients discharged after hospitalization for SARS-CoV-2 infection. This trial is a sub-study of the TICO (Therapeutics for Inpatients with COVID-19) study which is a Phase 3 randomized, blinded, controlled platform trial that allows investigational agents to be added and dropped during the course of the study for efficient testing of new agents against control (i.e., placebo + SOC) within the same trial infrastructure.

## Key facts

- **NIH application ID:** 10506007
- **Project number:** 75N91019D00024-P00001-759102000039-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** LAURA MCNAY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $15,147,252
- **Award type:** —
- **Project period:** 2020-09-02 → 2023-06-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10506007

## Citation

> US National Institutes of Health, RePORTER application 10506007, Vaccination for Recovered Inpatients with COVID-19 (VATICO) (75N91019D00024-P00001-759102000039-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10506007. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*